Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Forschungsstudie darüber, wie gut Concizumab bei Ihnen wirkt, wenn Sie an Hämophilie A oder B mit oder ohne Inhibitoren leiden (Explorer10)

17. September 2026 aktualisiert von: Novo Nordisk A/S

Offene Studie zur Untersuchung der Wirksamkeit, Sicherheit und Pharmakokinetik der Concizumab-Prophylaxe bei Kindern unter 12 Jahren mit Hämophilie A oder B mit oder ohne Inhibitoren

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.

Participants will have to inject the study medicine every day under the skin with a pen-injector.

The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

153

Phase

  • Phase 3

Erweiterter Zugriff

Nicht länger verfügbar außerhalb der klinischen Studie. Siehe erweiterter Zugriffsdatensatz.

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Algiers, Algerien, 16000
        • Haematology and Blood Bank Department
      • Constantine, Algerien, 25000
        • CHU Constantine BEN BADIS/ Hematology department
      • Banja Luka, Bosnien und Herzegowina, 78000
        • University Clinical Center of Republic Srpska (545)
      • Tuzla, Bosnien und Herzegowina, 75000
        • University Clinical Centre Tuzla
      • Plovdiv, Bulgarien, 4002
        • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
      • Sofia, Bulgarien, 1527
        • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
      • Varna, Bulgarien, 9010
        • UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
      • Tallinn, Estland, 13419
        • Tallinn Children's Hospital
      • Chambéry, Frankreich, 73000
        • Centre Hospitalier Metropole Savoie
      • Le Kremlin-Bicêtre, Frankreich, 94275
        • Ap-Hp-Hopital de Bicetre-1
      • Paris, Frankreich, 75015
        • AP-HP-HOPITAL NECKER_Service d'hématologie
      • Athens, Griechenland, GR-11527
        • Aghia Sophia Childrens' Hospital
      • Thessaloniki, Griechenland, GR 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Thessaloniki, Griechenland, 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
    • Assam
      • Guwahati, Assam, Indien, 781032
        • Guwahati Medical College
    • Gujarat
      • Surat, Gujarat, Indien, 395002
        • Nirmal Hospital Pvt. Ltd.
    • Maharashtra
      • Kolhāpur, Maharashtra, Indien, 416005
        • SSSH_Dept. of Clinical Haematology & Haemato Oncology
      • Mumbai, Maharashtra, Indien, 400012
        • Seth GS Medical College & KEM Hospital
      • Mumbai, Maharashtra, Indien, 400022
        • K.J Somaiya Hospital and Research Centre
      • Mumbai, Maharashtra, Indien, 400066
        • MCGM - Comprehensive Thalassemia Care
      • Pune, Maharashtra, Indien, 411004
        • Sahyadri Super Speciality Hospital
    • Odisha
      • Cuttack, Odisha, Indien, 753007
        • S.C.B. Medical College
    • Rajasthan
      • Jaipur, Rajasthan, Indien, 302004
        • J K Lon Hospital
    • Uttar Pradesh
      • Noida, Uttar Pradesh, Indien, 201303
        • Post Graduate Institute of Child Health
    • Uttart Pradesh
      • Lucknow, Uttart Pradesh, Indien, 226014
        • SGPGI
      • Catania, Italien, 95123
        • A.O.U policlinico "G. Rodolico-San Marco"
      • Florence, Italien, 50134
        • Dipartimento di Ematologia Univ. Firenze
      • Padova, Italien, 35128
        • Azienda Ospedaliera di Padova _
      • Parma, Italien, 43126
        • Azienda Ospedaliera-Universitaria Parma
      • Kanagawa, Japan, 216-8511
        • St. Marianna University School of Medicine Hospital_Pediatrics
      • Saitama, Japan, 330-8777
        • Saitama Children's Med Centre_Hematology-Oncology
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • BC Children's Hospital
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • McMaster Children's Hospital
      • Beirut, Libanon, 961
        • Saint George Hospital University Medical Center
      • Tripoli, Libanon, 1434
        • Hospital Nini
      • Vilnius, Litauen, LT-08406
        • Centre of Oncology and Hematology, Vilnius University
    • Kuala Lumpur
      • Kampung Baru, Kuala Lumpur, Malaysia, 50300
        • Hospital Tunku Azizah
    • Pulau Pinang
      • George Town, Pulau Pinang, Malaysia, 10450
        • Hospital Pulau Pinang
    • Sarawak
      • Kuching, Sarawak, Malaysia, 93586
        • Sarawak General Hospital
    • Terengganu
      • Kuala Terengganu, Terengganu, Malaysia, 20400
        • Hospital Sultanah Nur Zahirah
      • Skopje, Nordmazedonien, 1000
        • PHI University Clinic for Children's Diseases Skopje
      • Oslo, Norwegen, 0372
        • Klinisk forskningspost
      • Gdansk, Polen, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Lublin, Polen, 20-093
        • Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
      • Warsaw, Polen, 02-091
        • Uniwersyteckie Centrum Kliniczne WUM
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polen, 50-556
        • Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
      • Bucharest, Rumänien, 022328
        • Clinic of Haematology, Fundeni Clinical Institute
      • Cluj-Napoca, Rumänien, 400177
        • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
      • Oradea, Rumänien, 410469
        • Spitalul Clinic Judetean De Urgenta Bihor
      • Gothenburg, Schweden, 413 46
        • Sahlgrenska US - Koagulationscentrum
      • Barcelona, Spanien, 08035
        • Hospital Vall d'Hebron
      • Madrid, Spanien, 28046
        • Hospital Universitario La Paz
      • Málaga, Spanien, 29009
        • Hospital Regional Universitario de Málaga
    • Murcia
      • El Palmar, Murcia, Spanien, 30120
        • Hospital Virgen de la Arrixaca - Hematología
    • Gauteng
      • Parktown, Johannesburg, Gauteng, Südafrika, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
      • Bangkok, Thailand, 10400
        • Ramathibodi Hospital
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial Hospital_Bangkok_0
      • Bangkok, Thailand, 10700
        • Siriraj Hospital - Hematology and Oncology
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
    • Mueang Distirct,
      • Ubon Ratchathani, Mueang Distirct,, Thailand, 34000
        • Sunpasitthiprasong Hospital_Pediatrics Department
      • Adana, Türkei (türkiye), 01130
        • Acibadem Adana Hastanesi
      • Adana, Türkei (türkiye), 01130
        • Acıbadem Adana Hastanesi-Hematoloji
      • Izmir, Türkei (türkiye), 35100
        • Ege Universitesi Tip Fakultesi
      • Izmir, Türkei (türkiye), 35100
        • Ege Üniversitesi Hastanesi- Hematoloji
      • Samsun, Türkei (türkiye), 55139
        • Ondokuz Mayis University Medical Faculty Ped. Haematology
      • Samsun, Türkei (türkiye), 55139
        • Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
    • Beşevler/Ankara
      • Ankara, Beşevler/Ankara, Türkei (türkiye), 06500
        • Gazi University
      • Ankara, Beşevler/Ankara, Türkei (türkiye), 06500
        • Gazi Üniversitesi Hastanesi- Hematoloji
    • California
      • San Diego, California, Vereinigte Staaten, 92123
        • Rady Childrens Hosp San Diego
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • University of Colorado Hospital
    • Florida
      • Orlando, Florida, Vereinigte Staaten, 32806
        • Arnold Palmer Children's Hospital
      • Orlando, Florida, Vereinigte Staaten, 32827
        • Nemours Child Orlando Hem/Onc.
    • Georgia
      • Augusta, Georgia, Vereinigte Staaten, 30912
        • Augusta Univ/Childrens Hosp-GA
      • Savannah, Georgia, Vereinigte Staaten, 31404
        • Memorial Health University Medical Center
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Childrens Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46260
        • Indiana Hemophilia-Thromb Ctr
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten, 70121
        • Ochsner Clinic Foundation
      • New Orleans, Louisiana, Vereinigte Staaten, 70118
        • Children's Hosp-New Orleans
    • Missouri
      • Kansas City, Missouri, Vereinigte Staaten, 64108
        • The Children's Mercy Hospital
    • Nebraska
      • Omaha, Nebraska, Vereinigte Staaten, 68114
        • Children's Nebraska
    • North Carolina
      • Greenville, North Carolina, Vereinigte Staaten, 27834
        • ECU Sickle Cell Comp Clinic
    • Ohio
      • Columbus, Ohio, Vereinigte Staaten, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19134
        • St Christopher Hosp for Child
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Fort Worth, Texas, Vereinigte Staaten, 76104
        • Cook Children's Hospital-Hematology-Oncology
      • Houston, Texas, Vereinigte Staaten, 77030
        • Texas Children's Hospital_Houston
    • Virginia
      • Charlottesville, Virginia, Vereinigte Staaten, 22908
        • Pediatrics Hematology/Oncology Clinic Battle Building
      • Birmingham, Vereinigtes Königreich, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Vereinigtes Königreich, BS2 8BJ
        • University Hospitals Bristol & Weston NHS Foundation Trust
      • London, Vereinigtes Königreich, WC1N 3HR
        • Great Ormond Street Hospital for Children
      • London, Vereinigtes Königreich, SE1 7EH
        • Evelina London Children's Hospital - Haemophilia

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

  • Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.

  • For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.

  • For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)

    1. Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    2. Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    3. Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
  • For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)

    1. Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
    2. Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
  • For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.

Exclusion Criteria:

  • Known or suspected hypersensitivity to study intervention or related products.
  • Known inherited or acquired coagulation disorder other than congenital haemophilia.
  • Ongoing or planned Immune Tolerance Induction treatment.
  • History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Concizumab-naïve patients

Concizumab-naïve participants below 12 years of age at the time of consent/assent

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Experimental: Patients coming from compassionate use

Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of patient(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: Week 32

Measured in ng/mL

Week 32
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: Week 32

Measured in nM

Week 32
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: Week 32

Measured in ng/mL

Week 32
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: Prior to the concizumab administration at week 20

Measured in ng/mL

Prior to the concizumab administration at week 20
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Zeitfenster: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng*hr/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

24. März 2022

Primärer Abschluss (Tatsächlich)

21. April 2026

Studienabschluss (Geschätzt)

2. November 2029

Studienanmeldedaten

Zuerst eingereicht

15. November 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. November 2021

Zuerst gepostet (Tatsächlich)

26. November 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NN7415-4616
  • U1111-1247-7330 (Andere Kennung: World Health Organization (WHO))
  • 2020-000504-11 (EudraCT-Nummer)
  • jRCT2031220097 (Registrierungskennung: JAPIC)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .